|
D’Amico risk stratification
|
|
Low risk
|
13 (21%)
|
|
Intermediate risk
|
23 (37%)
|
|
High risk
|
26 (42%)
|
|
Median pre-treatment PSA level
|
13.7 ng/mL [1.5–94]
|
|
Gleason score
|
|
6
|
22 (35.5%)
|
|
7 (3 + 4)
|
18 (29%)
|
|
7 (4 + 3)
|
9 (14.5%)
|
|
≥ 8
|
13 (21%)
|
|
T Stage
|
|
T1a/b
|
5 (8%)
|
|
T1c
|
27 (43.5%)
|
|
T2
|
20 (32.5%)
|
|
T3a
|
5 (8%)
|
|
T3b
|
5 (8%)
|
|
N Stage
|
|
N0
|
60 (96.7%)
|
|
N1
|
2 (3.3%)
|
|
Prostate surgery
|
|
TURP
|
52 (84%)
|
|
Vaporization
|
2 (3%)
|
|
Adenectomy
|
8 (13%)
|
|
Androgen deprivation therapy
|
30 (48.5%)
|
|
Diabete mellitus (n = 61)
|
11 (18%)
|
|
Arterial hypertension (n = 61)
|
33 (54%)
|
|
Medical treatmenta
|
7 (11.3%)
|
|
Prostatic volume before surgery (n = 59)
|
59.5 cc [3–150]
|
|
Prostatic volume after surgery (n = 54)
|
26.8 cc [3–100]
|
|
Median RT dose
|
78.5 Gy [70–80]
|
|
70 Gy
|
3 (4.9%)
|
|
76 Gy
|
15 (24.2%)
|
|
80 Gy
|
44 (70.9%)
|
|
Whole-pelvis RT
|
6 (9.6%)
|
|
Bladder volume receiving 70 Gy (n = 57)
|
34.7 cc [1–86]
|
